1. Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?
   Charalampos Theocharopoulos et al, 2024, Cancer Treatment Reviews CrossRef
2. A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells
   Nadine Aschmoneit et al, 2021, Scientific Reports CrossRef
3. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release
   Nadine Aschmoneit et al, 2021, Journal for ImmunoTherapy of Cancer CrossRef
4. Advances in conjugate drug delivery System: Opportunities and challenges
   Yi-Shen Zhu et al, 2024, International Journal of Pharmaceutics CrossRef
5. HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs
   Huilan Zeng et al, 2024, Cancer Drug Resistance CrossRef
6. HER3 in cancer: from the bench to the bedside
   Lucía Gandullo-Sánchez et al, 2022, Journal of Experimental & Clinical Cancer Research CrossRef
7. EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate
   Sandra Bibbò et al, 2024, Journal of Controlled Release CrossRef
8. HER3: Updates and current biology function, targeted therapy and pathologic detecting methods
   Leyi Gao et al, 2024, Life Sciences CrossRef